Biontech Se ADR (BNTX) Stock Price, Quote & News

Company Profile

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin a...

Industry: Biotechnology

Sector: Healthcare

Phone: 49 6131 9084

Fax: 49 6131 9084

Website: www.biontech.de

Address:

An der Goldgrube 12, Mainz, Germany

taxplanr Jun. 22 at 12:28 AM

$BNTX $MRNA $PFE front line observation https://www.tiktok.com/t/ZTBWQPf5x/

0 · Reply

Ventureville Jun. 19 at 5:53 PM

Healthcare remains one of the most asymmetric sectors in the market. $BVAXF $MRNA $BNTX $ALT $SAVAW Innovation drives value.

1 · Reply

Novasqueeze Jun. 18 at 7:34 PM

And yet $BNTX reported -€1.14B net loss$MRNA -$2.8B net loss and $NVAX +$440 million net income so being the only profitable company of all 3 in 2025. Now the question is if it can sustain profitability year over year even if it’s not much or will it be as NVAX said in 2028. MRNA said target 2028 and BNTX has no target at all but maybe 2028 according to analysts. So in that context, we just need another Sanofi type of big deal to break out. Hopefully we see one in 2026. Because sitting at a 1.5B market cap is kind of ridiculous at this point.

1 · Reply

Novasqueeze Jun. 18 at 7:21 PM

$NVAX +30% $MRNA +150% $BNTX -15% in one year. They have diverged a lot past year. BNTX AND MRNA now at the same market cap of 25B while NVAX is at 1.5B 🤣🤣🤣 NVAX only needs to do +1600% to match the other 2. I know it’s not even in the same league and same business anymore

0 · Reply

IndyOne Jun. 18 at 6:42 PM

$MRNA YES!!! After 8 hours of VRBPAC vetting. The win and a watershed moment for a new drug platform that is superior to exisiting alternatives. mRNA-1010 WIN. More to come, 20 more products moving forward to commercialization. There will be backorders. We are buying $BNTX production facilities. BioNTech investors, you know the value of mRNA technology - please consider a position in MRNA. Diversification is important. Special meeting coming up for Moderna on June 25th. Much more coming.

1 · Reply

eightytwentie Jun. 18 at 1:12 PM

$BNTX rotation of smart money into pharmaceuticals, biotech $TGTX $MRNA

1 · Reply

taxplanr Jun. 18 at 12:03 AM

$BNTX $MRNA $BMY $MRK Ivermectin on ABC news https://www.tiktok.com/t/ZTBbSwqjb/

0 · Reply

Pearl_Power Jun. 17 at 6:25 PM

$BNTX could be something

1 · Reply

GoParabolic Jun. 16 at 9:29 AM

$BNTX will move fast and surprise $NVDA $TSLA $SPCX $PFE

0 · Reply

GoParabolic Jun. 16 at 9:25 AM

$BNTX will follow $SPCX $NVDA $AAPL $AMZN

0 · Reply

Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO

MRNA

2026-05-31T21:45:07.000Z - 21 days ago

BioNTech, Bristol announce interim Phase 2 data from Rosetta Lung-02 trial

BMY

May 30, 2026, 2:15 PM EDT - 22 days ago

Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

May 27, 2026, 11:07 AM EDT - 25 days ago

This Biotech's Cancer Portfolio Could End Its Rough Patch

2026-05-27T08:45:10.000Z - 26 days ago

BioNTech upgraded to Buy from Neutral at UBS

May 22, 2026, 5:00 AM EDT - 4 weeks ago

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

2026-05-21T21:20:11.000Z - 4 weeks ago

Bernstein starts BioNTech at Market Perform, sees high registration risk

2026-05-21T20:27:55.000Z - 4 weeks ago

BioNTech initiated with a Market Perform at Bernstein

May 15, 2026, 4:15 PM EDT - 5 weeks ago

BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026

May 15, 2026, 8:00 AM EDT - 5 weeks ago

BioNTech SE Transcript: AGM 2026

2026-05-12T08:30:54.000Z - 5 weeks ago

Berenberg cuts BioNTech target, says shares ‘deeply’ undervalued

2026-05-07T14:04:55.000Z - 6 weeks ago

BioNTech announces new $1B ADS repurchase program

May 7, 2026, 6:45 AM EDT - 6 weeks ago

BioNTech Announces New ADS Repurchase Program

2026-05-07T07:26:08.000Z - 6 weeks ago

BioNTech price target lowered to $158 from $171 at Canaccord

May 6, 2026, 7:44 AM EDT - 6 weeks ago

Germany says vaccine supply secure despite BioNTech production loss

2026-05-05T15:41:20.000Z - 6 weeks ago

BioNTech to cut up to 1,860 jobs, close multiple global sites, Reuters reports

PFE

May 5, 2026, 8:00 AM EDT - 6 weeks ago

BioNTech SE Earnings Call Transcript: Q1 2026

May 5, 2026, 8:00 AM EDT - 6 weeks ago

BioNTech SE Earnings release: Q1 2026

May 5, 2026, 8:00 AM EDT - 6 weeks ago

BioNTech SE Slides: Q1 2026

May 5, 2026, 7:26 AM EDT - 6 weeks ago

BioNTech to Close Sites, Cut Quarter of Workforce in Savings Push

2026-05-05T11:14:49.000Z - 6 weeks ago

BioNTech reaffirms FY26 revenue view EUR2.000B- EUR2.300B

May 5, 2026, 6:47 AM EDT - 6 weeks ago

BioNTech to close sites in Germany, Singapore affecting 1,860 staff

May 5, 2026, 6:45 AM EDT - 6 weeks ago

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

Apr 21, 2026, 5:35 PM EDT - 2 months ago

Two experimental drugs showed striking early results against pancreatic cancer

RVMD

Apr 21, 2026, 6:45 AM EDT - 2 months ago

BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026

2026-04-13T12:01:10.000Z - 2 months ago

BioNTech price target raised to $130 from $128 at BofA

2026-04-12T16:20:47.000Z - 2 months ago

BioNTech announce Phase 2 cohort of BNT323 met primary efficacy endpoint

Apr 11, 2026, 7:00 AM EDT - 2 months ago

BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

2026-04-10T13:03:03.000Z - 2 months ago

BioNTech price target raised to $126 from $125 at Morgan Stanley

Apr 1, 2026, 11:39 AM EDT - 2 months ago

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

PFE

2026-03-31T10:16:25.000Z - 2 months ago

BioNTech price target lowered to $130 from $140 at H.C. Wainwright

Mar 24, 2026, 6:45 AM EDT - 3 months ago

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

Mar 10, 2026, 2:48 PM EDT - 3 months ago

BioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 10, 2026, 1:29 PM EDT - 3 months ago

One simple reason why BioNTech stock is a raging buy on today's crash

Mar 10, 2026, 8:00 AM EDT - 3 months ago

BioNTech SE Earnings Call Transcript: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 3 months ago

BioNTech SE Annual report: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 3 months ago

BioNTech SE Earnings release: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 3 months ago

BioNTech SE Slides: Q4 2025

Mar 10, 2026, 7:40 AM EDT - 3 months ago

Scientists behind COVID-19 vaccine will depart BioNTech

Mar 10, 2026, 7:18 AM EDT - 3 months ago

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock.

Mar 10, 2026, 6:50 AM EDT - 3 months ago

BioNTech Cofounders to Leave to Form New Company

Mar 10, 2026, 6:49 AM EDT - 3 months ago

BioNTech's founding couple Sahin, Tuereci to leave to set up new venture

Mar 10, 2026, 6:45 AM EDT - 3 months ago

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

Mar 10, 2026, 6:33 AM EDT - 3 months ago

BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030

Feb 24, 2026, 6:45 AM EST - 4 months ago

BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026

Feb 19, 2026, 1:25 PM EST - 4 months ago

BioNTech sues Moderna for patent infringement over COVID-19 shots

MRNA

Jan 28, 2026, 8:00 AM EST - 5 months ago

BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

Jan 13, 2026, 5:15 PM EST - 5 months ago

BioNTech SE Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 5:15 PM EST - 5 months ago

BioNTech SE Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 6:45 AM EST - 5 months ago

BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

Jan 9, 2026, 10:00 AM EST - 5 months ago

University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences Fund

Dec 18, 2025, 4:45 AM EST - 6 months ago

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

Dec 9, 2025, 7:00 AM EST - 6 months ago

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

BMY

Dec 6, 2025, 3:30 PM EST - 7 months ago

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

Dec 3, 2025, 9:01 AM EST - 7 months ago

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

CVAC

Dec 1, 2025, 3:50 PM EST - 7 months ago

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

MRNA NVAX PFE

Dec 1, 2025, 12:35 PM EST - 7 months ago

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

MRNA NVAX PFE

Nov 26, 2025, 7:30 AM EST - 7 months ago

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

Nov 13, 2025, 5:20 PM EST - 7 months ago

Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up

PFE

Nov 13, 2025, 8:17 AM EST - 7 months ago

BioNTech says collaboration with Pfizer remains unchanged

PFE

Nov 11, 2025, 9:00 AM EST - 7 months ago

BioNTech SE Transcript: R&D Day

Nov 11, 2025, 9:00 AM EST - 7 months ago

BioNTech SE Slides: R&D Day

Nov 3, 2025, 8:00 AM EST - 8 months ago

BioNTech SE Earnings Call Transcript: Q3 2025

Nov 3, 2025, 8:00 AM EST - 8 months ago

BioNTech SE Earnings release: Q3 2025

Nov 3, 2025, 8:00 AM EST - 8 months ago

BioNTech SE Slides: Q3 2025

Nov 3, 2025, 6:47 AM EST - 8 months ago

BioNTech lifts 2025 revenue guidance on BMS partnership payment

Nov 3, 2025, 6:45 AM EST - 8 months ago

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

Oct 28, 2025, 7:45 AM EDT - 8 months ago

BioNTech to Host Innovation Series R&D Day on November 11, 2025

Oct 27, 2025, 7:45 AM EDT - 8 months ago

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

Oct 22, 2025, 6:45 AM EDT - 8 months ago

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

Oct 1, 2025, 9:00 AM EDT - 9 months ago

BioNTech SE Transcript: AI Day 2025

Oct 1, 2025, 9:00 AM EDT - 9 months ago

BioNTech SE Slides: FY 2025

Sep 23, 2025, 6:45 AM EDT - 9 months ago

BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025

Sep 19, 2025, 11:40 AM EDT - 9 months ago

Mizuho's Jared Holz: There's not much value left in vaccine stocks

MRNA NVAX PFE

Sep 12, 2025, 1:37 PM EDT - 10 months ago

COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says

JNJ KVUE MRNA PFE

Sep 8, 2025, 11:05 AM EDT - 10 months ago

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

BMY

Sep 8, 2025, 11:00 AM EDT - 10 months ago

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

Sep 8, 2025, 7:02 AM EDT - 10 months ago

Pfizer, partner BioNTech say updated COVID shot shows better immune response

PFE

Sep 8, 2025, 6:45 AM EDT - 10 months ago

Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

PFE

Sep 5, 2025, 5:13 AM EDT - 10 months ago

BioNTech, Duality score initial trial win with breast cancer precision drug

taxplanr Jun. 22 at 12:28 AM

$BNTX $MRNA $PFE front line observation https://www.tiktok.com/t/ZTBWQPf5x/

0 · Reply

Ventureville Jun. 19 at 5:53 PM

Healthcare remains one of the most asymmetric sectors in the market. $BVAXF $MRNA $BNTX $ALT $SAVAW Innovation drives value.

1 · Reply

Novasqueeze Jun. 18 at 7:34 PM

1 · Reply

Novasqueeze Jun. 18 at 7:21 PM

0 · Reply

IndyOne Jun. 18 at 6:42 PM

1 · Reply

eightytwentie Jun. 18 at 1:12 PM

$BNTX rotation of smart money into pharmaceuticals, biotech $TGTX $MRNA

1 · Reply

taxplanr Jun. 18 at 12:03 AM

$BNTX $MRNA $BMY $MRK Ivermectin on ABC news https://www.tiktok.com/t/ZTBbSwqjb/

0 · Reply

Pearl_Power Jun. 17 at 6:25 PM

$BNTX could be something

1 · Reply

GoParabolic Jun. 16 at 9:29 AM

$BNTX will move fast and surprise $NVDA $TSLA $SPCX $PFE

0 · Reply

GoParabolic Jun. 16 at 9:25 AM

$BNTX will follow $SPCX $NVDA $AAPL $AMZN

0 · Reply

Ventureville Jun. 15 at 3:17 PM

Biotech sector surging on oncology innovation. $BIOV $BVAXF cancer vaccine progress stands strong next to $MRNA, $BNTX, and $GILD. Pipeline momentum building fast. Bullish across the board!

0 · Reply

SoYeonPicks Jun. 15 at 3:05 PM

$BNTX multiple shots on goal here 😇

0 · Reply

Pardes1122 Jun. 13 at 8:15 PM

$BNTX

0 · Reply

birdflustocks Jun. 13 at 7:28 PM

$BNTX mRNA-based tuberculosis vaccines BNT164a1 and BNT164b1 are immunogenic, well tolerated and efficacious in rodent models https://link.springer.com/article/10.1038/s41590-026-02545-z

1 · Reply

IndyOne Jun. 12 at 8:51 PM

$BNTX Nice run and a bit unexpected.

0 · Reply

AIIAAIIA_88 Jun. 11 at 3:27 PM

$BNTX Up with great volume. The volume today is already more than the average daily volume! And up 3%. It will be great!

0 · Reply

wheresdannynow Jun. 10 at 2:48 PM

$BVAXF is now on my biotech watchlist. Clinical-stage immunotherapy, DPX platform, oncology angle, and the kind of microcap setup that can get violent when volume hits. Watching beside $MRNA $BNTX $IOVA $XBI. High risk. High torque. Eyes open.

1 · Reply

Pillemann1 Jun. 10 at 11:53 AM

$BNTX what is wrong here. It gived me turning the key and throw it away kind of vibes….

0 · Reply

taxplanr Jun. 9 at 12:33 PM

$BNTX $MRNA $MRK $BMY do you know why RNA programming will never work even for cancer? https://www.instagram.com/reel/DZLfm1EybwI/?igsh=b2ZiaG9vOGs5MXd0

1 · Reply

Lambo2 Jun. 9 at 2:03 AM

$BNTX

0 · Reply

AIIAAIIA_88 Jun. 6 at 10:52 PM

$BNTX It looks like $88 area is safe to buy zone. It refuses to go down much below this price level and the company has a great pipeline with still many milestone events during the rest of the year. JMO

0 · Reply

truehealthvalue Jun. 5 at 9:34 AM

$BNTX I would look at $ELTX, About to take off, it will be worth billions in a short time

1 · Reply

Market Cap	22.98B
Revenue (ttm)	3.25B
Net Income (ttm)	-1.29B
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-39.59%
Debt to Equity Ratio	0.02

Volume	939,500
Avg Vol	999,190
Day's Range	N/A - N/A
Shares Out	252.88M
Stochastic %K	72%
Beta	1.32
Analysts	Strong Sell
Price Target	$130.50